Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?
about
Metabolic syndrome and renal cell carcinomaCritical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinomaSerum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranibAssociation between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinomaPrognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case seriesObesity triggers enhanced MDSC accumulation in murine renal tumors via elevated local production of CCL2.Impact of body composition on clinical outcomes in metastatic renal cell cancer.Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patientsObesity and Outcomes in Patients with Metastatic Urothelial Carcinoma.A pilot study of temsirolimus and body composition.Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study.Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.Visceral adiposity and cancer survival: a review of imaging studies.Prognostic significance of visceral obesity in patients with advanced renal cell carcinoma undergoing nephrectomy.The association between renal sinus fat area and the progression-free survival in Chinese non-metastatic clear-cell renal cell carcinoma patientsSkeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies.The Plausibility of Obesity Paradox in Cancer-Point.
P2860
Q26825147-9DE1B5C4-9AAD-46A1-934C-24C18ECBC273Q33754122-79A8CD4B-9FAF-47E0-9D92-210F20EEADCCQ34354522-20ED80A0-73AF-4EF3-8CFC-40B0E89EF063Q34436020-6A9EA913-B251-46BF-901D-56B1C5C2F43CQ35068826-D82C6673-9666-415E-A709-1DEC6520164BQ35175098-E2DD84F2-AE79-47C2-9937-8814D7E41A3EQ35599762-FED915AC-7E79-4C2D-A413-21169769C204Q36124825-FE2730AC-8071-4726-A3CB-03D579B5B7F9Q37002783-2F2C79CF-BEF6-4E0F-8240-5CDFF8A07072Q37144827-AD319DDB-AEB2-49E0-B206-4A772E3B51A0Q37313713-E5D550D4-6369-4056-BAC8-75626C00ED9DQ38062025-541BDB20-7AD9-4042-8809-701892520427Q38176985-18CB5C94-1A34-4A72-B2D8-CEA7D18A0ED1Q39030345-5740D270-68C9-44B7-8749-4CAAFC3A7F56Q41512003-E7DC3B16-3F7E-4DD1-90DF-572DE1FBBED3Q42371548-C44ED25A-4D18-4ECE-BF7D-D1FB10D59EC9Q46299111-58871E6C-531D-46D5-8A8E-557DE38A115EQ51833803-0DDA00F3-B0D1-4822-815C-B83367C9C209Q52655425-A5170C65-D9BC-43EB-93DB-0AB6C5C0FFF3Q53059526-DD2745EB-7A01-40F7-A1C3-8729FA579360Q53073930-6FC565FB-C600-413C-9DC8-AD98D8C72496
P2860
Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Does obesity influence the pro ...... rowth factor-targeted therapy?
@ast
Does obesity influence the pro ...... rowth factor-targeted therapy?
@en
type
label
Does obesity influence the pro ...... rowth factor-targeted therapy?
@ast
Does obesity influence the pro ...... rowth factor-targeted therapy?
@en
prefLabel
Does obesity influence the pro ...... rowth factor-targeted therapy?
@ast
Does obesity influence the pro ...... rowth factor-targeted therapy?
@en
P2093
P2860
P1433
P1476
Does obesity influence the pro ...... rowth factor-targeted therapy?
@en
P2093
Andres J Schrader
Christoph Seidel
Frank Wacker
Hendrik Eggers
Kristina I Ringe
Mark Schrader
Markus A Kuczyk
Sandra Steffens
Viktor Grünwald
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0213
P577
2011-10-21T00:00:00Z